Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1252 - 1252
Published: April 7, 2025
The gut microbiome plays a pivotal role in modulating cancer therapies, including immunotherapy and chemotherapy. Emerging evidence demonstrates its influence on treatment efficacy, immune response, resistance mechanisms. Specific microbial taxa enhance checkpoint inhibitor while dysbiosis can contribute to adverse outcomes. Chemotherapy effectiveness is also influenced by composition, with engineered probiotics prebiotics offering promising strategies drug delivery reduce toxicity. Moreover, metabolites, such as short-chain fatty acids, systems have shown potential improve therapeutic responses. These findings underscore the importance of personalized microbiome-based approaches optimizing treatments.
Language: Английский